MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage several intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Key trial goals have been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis people, while among the exploratory objectives https://delcasertib58901.tribunablog.com/considerations-to-know-about-qst4-45333735